Three biotechs line up for IPOs amid market skittishness

A trio of small drug developers are queuing up to go public as the years-long open window for biotech IPOs continues to falter. Viventia Bio, developing treatments for cancer, and Kura Oncology each filed to raise $86 million, while Dutch oncology biotech Merus lined up for a $60 million debut. Meanwhile, most of the past month's biotech debutantes have priced their IPOs at significant discounts, as marketwide concerns about drug pricing and R&D success have driven down valuations across the biopharma industry. Viventia | Kura | Merus

Suggested Articles

Horizon Therapeutics is expanding its U.S. footprint to the Bay Area—the company unveiled a new R&D and manufacturing site in South San Francisco.

Azeria Therapeutics has raised £32 million ($41 million) to take its estrogen receptor positive breast cancer program into the clinic.

Biogen’s Al Sandrock has given a bullish assessment of Alzheimer’s disease drug aducanumab. The head of R&D at Biogen thinks the drug works, despite i